KRAS vaccine for advanced solid tumors
Treatments studied
Part of Cancer clinical trials.
This trial tests a vaccine that targets a specific genetic change (KRAS mutation) in advanced solid tumors like pancreatic and lung cancer. The vaccine is designed to help your immune system fight cancer cells with this mutation.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have a solid tumor (like pancreatic or lung cancer) that has a KRAS mutation (G12C, G12D, G12R, or G12V).
- You have tried standard treatments and they didn't work, or you have no standard options, or you have minimal residual disease after treatment.
- You have a specific immune system marker called HLA-A*1101.
- You are generally healthy enough to be active (ECOG score 0-1) and have a life expectancy of at least 6 months.
- You have measurable tumors on CT or MRI scans.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two new drugs together for people with advanced solid tumors that have a specific genetic change called KRAS G12C. The treatment may help shrink tumors or slow their growth.
This study tests a new treatment for people with advanced solid tumors that have a specific genetic change called KRAS G12V. The treatment is designed to help the immune system attack cancer cells with this mutation, and the study aims to see if it is safe and effective.
This trial tests a vaccine designed to target cancers with KRAS mutations. It may be an option if your cancer has a KRAS mutation and you have either tried other treatments without success or have a newly diagnosed, early-stage lung adenocarcinoma.
This trial tests a new vaccine that targets KRAS mutations in patients with colorectal or pancreatic cancer after surgery and chemotherapy. The goal is to see if the vaccine can help prevent the cancer from coming back.
This early-phase trial is testing a new mRNA vaccine (ABO2102) designed to target KRAS mutations in advanced solid tumors. It may be an option if your cancer has a KRAS mutation and standard treatments are no longer working.
This trial tests a new type of immune cell therapy (TCR-T) designed to attack cancer cells with a specific KRAS mutation. It may be an option for people with advanced solid tumors who have run out of standard treatments.
Hear when a new Advanced Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.